Aveo Pharmaceuticals Inc Quick Ratio (AVEO) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aveo Pharmaceuticals Inc   (AVEO)

Aveo Pharmaceuticals Inc 's Quick Ratio

AVEO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 1.82 below Aveo Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Aveo Pharmaceuticals Inc in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 1504 to 1790.

Explain Quick Ratio?
How much Cash & cash equivalents AVEO´s has?
What are AVEO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AVEO Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change 89.59 % 80.24 % -4.3 % 10.54 % 34.08 %
Y / Y Cash & cash equivalent Change -17.68 % -25.03 % -34.9 % 41.39 % 36.56 %
Quick Ratio MRQ 1.82 2.45 3.89 4.66 4.2
AVEO's Total Ranking # 1790 # 1504 # 1120 # 996 # 373
Seq. Current Liabilities Change 34.69 % 55.13 % 8.4 % -16.29 % 28.05 %
Seq. Cash & cash equivalent Change 0.31 % -2.38 % -9.49 % -7.12 % -8.65 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 761
Overall Market # 1790


Quick Ratio Statistics
High Average Low
8.96 3.4 0.83
(Mar 31 2012)   (Mar 31 2018)




Financial Statements
Aveo Pharmaceuticals Inc 's Current Liabilities $ 42 Millions Visit AVEO's Balance sheet
Aveo Pharmaceuticals Inc 's Cash & cash equivalent $ 77 Millions Visit AVEO's Balance sheet
Source of AVEO's Sales Visit AVEO's Sales by Geography


Cumulative Aveo Pharmaceuticals Inc 's Quick Ratio

AVEO's Quick Ratio for the trailling 12 Months

AVEO Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 44.79 % 28.46 % 2.94 % 3.03 % -4.43 %
Y / Y Cash & cash equivalent TTM Growth -15.57 % -4.9 % 12.31 % 72.13 % 71.49 %
Quick Ratio TTM 2.84 3.63 4.61 5.08 4.87
Total Ranking TTM # 4650 # 1029 # 874 # 485 # 3960
Seq. Current Liabilities TTM Growth 21.58 % 17.78 % -1.14 % 2.29 % 7.86 %
Seq. Cash & cash equivalent TTM Growth -4.92 % -7.09 % -10.45 % 6.73 % 7.09 %

Quick ratio ranking by company, industry and sector >> Back to AVEO Financial Strength Comparisons >> Go to Compare AVEO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2022 to $42.42 millions, cumulative Quick Ratio decreased to 2.84 above the AVEO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 592 other companies have achieved higher Quick Ratio than Aveo Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 1029 to 4650.

Explain Quick Ratio?
How much Cash & cash equivalents AVEO´s has?
What are AVEO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 593
Healthcare Sector # 1176
Within the Market # 4650


trailing twelve months Quick Ratio Statistics
High Average Low
5.18 2.79 0.98
(Dec 31 2021)   (Sep 30 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Bellicum Pharmaceuticals Inc   5.00 $ 28.756  Millions$ 5.748  Millions
Amylyx Pharmaceuticals Inc   4.98 $ 162.593  Millions$ 32.647  Millions
Plx Pharma Inc   4.97 $ 25.834  Millions$ 5.200  Millions
Korro Bio Inc   4.97 $ 99.347  Millions$ 20.003  Millions
Igc Pharma Inc   4.93 $ 6.816  Millions$ 1.382  Millions
Virpax Pharmaceuticals Inc   4.89 $ 20.563  Millions$ 4.208  Millions
Neximmune Inc   4.88 $ 45.860  Millions$ 9.394  Millions
Tg Therapeutics Inc   4.83 $ 175.942  Millions$ 36.447  Millions
Decibel Therapeutics Inc   4.79 $ 111.946  Millions$ 23.374  Millions
Novabridge Biosciences  4.75 $ 500.121  Millions$ 105.191  Millions
Verastem Inc   4.75 $ 103.976  Millions$ 21.873  Millions
Ampio Pharmaceuticals inc   4.72 $ 16.947  Millions$ 3.592  Millions
Bridgebio Pharma Inc   4.68 $ 558.315  Millions$ 119.194  Millions
Proqr Therapeutics N v   4.49 $ 106.148  Millions$ 23.645  Millions
Galmed Pharmaceuticals Ltd   4.46 $ 13.785  Millions$ 3.094  Millions
Praxis Precision Medicines Inc   4.42 $ 123.740  Millions$ 28.006  Millions
Imunon Inc   4.41 $ 37.352  Millions$ 8.465  Millions
Trevena inc   4.36 $ 40.392  Millions$ 9.257  Millions
Adial Pharmaceuticals Inc   4.34 $ 5.753  Millions$ 1.327  Millions
Regulus Therapeutics Inc   4.31 $ 45.324  Millions$ 10.521  Millions
Revelation Biosciences Inc   4.24 $ 6.195  Millions$ 1.463  Millions
Ultragenyx Pharmaceutical Inc   4.18 $ 888.675  Millions$ 212.584  Millions
Spyre Therapeutics Inc   4.17 $ 73.676  Millions$ 17.678  Millions
Gt Biopharma Inc   4.14 $ 20.784  Millions$ 5.025  Millions
Ocular Therapeutix Inc   4.13 $ 120.950  Millions$ 29.269  Millions
Theriva Biologics inc   4.10 $ 50.490  Millions$ 12.323  Millions
Sarepta Therapeutics Inc   4.03 $ 2,072.484  Millions$ 513.672  Millions
Summit Therapeutics Inc   4.01 $ 61.903  Millions$ 15.436  Millions
Siga Technologies Inc  4.00 $ 109.750  Millions$ 27.456  Millions
Impel Pharmaceuticals Inc   3.99 $ 79.731  Millions$ 19.963  Millions

Date modified: 2026-09-08T15:10:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.